

4. *Κούμαρης* <sup>2</sup>I. Γ., Τὸ τρίχωμα τοῦ ἀνθρώπου. Περιοδικὸν «<sup>3</sup>Ἡλιος»: ἔτ. (1947). τεύχη: 176, 179, 181, 182, 183, 184).
5. *Martin R.* Lehrbuch der Anthropologie I III Band (G. Fischer) (1928).
6. *Μπίσης* I. Περὶ τοῦ χρώματος τῶν ὀφθαλμῶν τῶν ἀρχαίων καὶ νέων Ἑλλήνων. Πρακτικὰ Ἑλληνικῆς Ἀνθρωπολογικῆς Ἐταιρείας (1933).
7. *Pittard E.* Les peuples des Balkans (Recherches Anthropologiques) dans la Péninsule des Balkans spécialement dans la Dobroudja Gèneve et Lyon Paris (1920).
8. *Σκλαβοῦνος* Γ. Α. Τὸ χροῶμα τῶν τριχῶν τῶν νέων Ἑλλήνων. Ἀνακοίνωσις γενομένη ἐνώπιον τῆς Ἀκαδημίας Ἀθηνῶν τῇ 27 Μαΐου 1943 καὶ περιοδικὸν «<sup>3</sup>Ἡλιος»: (1946). (Τεύχη 136-140).
9. *Τσάκωνας* Σ. Στατιστικὴ ἀναστήματος, διαμέτρων πύελου, χροιαῖς δέρματος κλπ. τῶν Ἑλληνίδων ἀπὸ μαιευτικῆς ἀπόψεως, Ἱατρικὴ Πρόοδος 1906, σελ. 219.
10. *Wateff S.* Anthropologische Beobachtungen an den Schülern und Soldaten in Bulgarien Corr. Bl. Anthrop. Ges. Jhg. 32 (1910). Nr 4, Σ 29/30 (ἐν Martin).
11. *Wiaczemsky.* La coloration des cheveux, des yeux et de la peau chez les Serbes. Anthrop., Bd. 20, (1909) σελ. 353 (ἐν Martin).

ΦΑΡΜΑΚΟΛΟΓΙΑ.—**Action of bromides to the body temperature and pyrogen test, by G. Logaras\***. Ἀνεκοινώθη ὑπὸ τοῦ κ. Γ. Ἰωκείμογλου.

In routine testing of parenteral solutions for pyrogens we have observed that a solution containing 3%  $\text{CaBr}_2$  and 5% Calcium gluconate, lowers the body temperature of rabbits by 1 to 3° C below the initial temperature. This fall of the normal temperature has been also recorded by others in isotonic solutions of sodium chloride (1) but amounts only to 0.1—0.3° C. This fact is important and it should be taken note of in testing for pyrogens. In the experiments we are reproducing below we were concerned to find out a) whether this effect prevents the pyrogen from causing a rise in body temperature b) how this effect could be abolished and c) whether bromides have an antipyretic effect.

\* ΓΕΩΡΓ. ΛΟΓΑΡΑΣ: Ἐνέργεια τῶν βρωμιούχων ἐπὶ τῆς θερμοκρασίας τοῦ σώματος.

## METHODS

*Pyrogens.* To test for pyrogens the U.S.P. XIII method on rabbits was used.

*Antipyretic effect.* Rats of a Wistar strain and both sexes, weighing 200 — 300 gm, were used.

Pyrexia was induced by subcutaneous injection of 10 cc/kg body weight of a 15% suspension of dried yeast. Calcium bromide and acetylsalicylic acid were administered intraperitoneally or subcutaneously.

## RESULTS

It is necessary to take into account the toxicity of  $\text{CaBr}_2$  and sodium salicylate and allow a sufficient margin between the doses employed in pyretic animals and the maximum dose tolerated by normal rats. Intraperitoneally the following results have been obtained.

| 3 per cent $\text{CaBr}_2$ +5 per cent Ca gluconate | Number of rats injected | Number died |
|---|-------------------------|-------------|
| $\text{CaBr}_2$ 0.87 gm per kg                      | 10                      | 10          |
| $\text{CaBr}_2$ 0.7 gm per kg                       | 5                       | 5           |
| $\text{CaBr}_2$ 0.52 gm/kg                          | 4                       | 4           |
| $\text{CaBr}_2$ 0.35 gm/kg                          | 15                      | 10          |
| $\text{CaBr}_2$ 0.26 gm/kg                          | 20                      | 3           |
| $\text{CaBr}_2$ 0.15 gm/kg                          | 10                      | 0           |
| 10% Sod. salicylate                                 |                         |             |
| 0.05 gm/kg  | 9                       | 0           |
| 0.1 gm/kg   | 15                      | 10          |
| 0.15 gm/kg  | 15                      | 13          |

The results are tabulated in tables I, II, and III and figures 1 and 2.

Figure 1 reproduces several temperature curves in normal rabbits after intravenous injection of a solution of  $\text{CaBr}_2$  3.0%+5% Calcium gluconate in a dose of 10 cc/kg body weight. By diluting the solution with sterile pyrogen free water 1:5 or 1:10 the antipyretic effect is no more noticeable and only the pyrogenic effect shown (Figure 2 and Table III).




Fig. 1.

TABLE I.

*Antipyretic effect of Calcium bromide.*

| Number of rats | dosage  | Average maximum rise in temperature ° C |
|----------------|---|---|
| 7              | suspension of dried yeast                           | + 0.8                                   |
| 15             | Yeast+CaBr <sub>2</sub> 0.015 g./100 g. body weight | - 0.70                                  |
| 7              | Yeast+0.01 g. Acetylsalicylic acid                  | - 1.75                                  |




Fig. 2.

TABLE II.

*Antipyretic effect of Potassium bromide*

| Number of rats | Dosage                             | Average maximum rise in temperature ° C |
|----------------|------------------------------------|---|
| 8              | 0.015 g/100 g KBr                  | + 0.7                                   |
| 5              | Controls suspension of dried yeast | + 1.3                                   |
| 5              | 0.01 g/100 g Acetyl-salicylic acid | + 0.3                                   |



TABLE III.

| Solution injected  | Body weight of Rabbit | Initial temperature | Hourly deviation from the initial temperature after injection |      |      | maximum rise or fall in temperature |
|--|-----------------------|---------------------|---|------|------|-------------------------------------|
|  |                       |                     | 1   | 2    | 3    |                                     |
|  |                       | °C                  | °C  | °C   | °C   |                                     |
| Solution of 3% CaBr <sub>2</sub> +5% Calcium gluconate . . . . . A | 1.27                  | 39.8                | -0.8  | -0.6 | -0.2 | -0.8                                |
|  | 1.7                   | 39.6                | -0.6  | 0.0  | +0.3 | -0.6                                |
|  | 1.52                  | 39.6                | -1.6  | -1.3 | -0.4 | -1.6                                |
| Solution of 3% CaBr <sub>2</sub> +5% Calcium gluconate . . . . . B | 1.5                   | 39.5                | -1.4  | -0.7 | -0.4 | -1.4                                |
|  | 1.77                  | 39.7                | -0.7  | -0.3 | -0.4 | -0.7                                |
|  | 1.77                  | 39.7                | -0.7  | -0.1 | 0.0  | -0.7                                |
| Solution of 3% CaBr <sub>2</sub> +5% Calcium gluconate . . . . . C | 1.22                  | 39.6                | -0.8  | -0.2 | +0.3 | -0.8                                |
|  | 1.15                  | 39.8                | -0.6  | -0.4 | -0.3 | -0.5                                |
|  | 1.1                   | 39.3                | -1.3  | -0.5 | -0.7 | -1.7                                |
| Solution of 3% CaBr <sub>2</sub> +5% Calcium gluconate . . . . . D | 1.25                  | 39.5                | -0.8  | -0.7 | -0.2 | -0.8                                |
|  | 1.07                  | 39.7                | -0.5  | -0.4 | -0.2 | -0.6                                |
|  | 1.17                  | 39.4                | -0.6  | -1.1 | -0.9 | -1.1                                |
| Same diluted 1:10 . . . . . A                                      | 1.47                  | 39.6                | +0.8  | +0.3 | -0.2 | +0.8                                |
|  | 1.57                  | 39.5                | +1.1  | +0.5 | +0.1 | +1.1                                |
|  | 1.75                  | 39.5                | +1.7  | +1.1 | +1.5 | +1.7                                |
| Same diluted 1:10 . . . . . B                                      | 1.4                   | 39.8                | +0.2  | 0.0  | -0.2 | +0.2                                |
|  | 1.3                   | 39.9                | 0.0   | 0.0  | -0.3 | 0.0                                 |
|  | 1.4                   | 39.5                | -0.1  | +0.1 | +0.1 | 0.1                                 |
| Same diluted 1:10 . . . . . C                                      | 1.12                  | 39.2                | +0.6  | +1.1 | +0.5 | +1.1                                |
|  | 1.1                   | 39.8                | +0.3  | +0.6 | +0.5 | +0.6                                |
|  | 1.12                  | 39.7                | +0.1  | +0.2 | +0.1 | +0.2                                |
| Same diluted 1:5 . . . . . D                                       | 1.0                   | 39.3                | +0.2  | -0.2 | -0.3 | +0.2                                |
|  | 1.15                  | 39.6                | -0.3  | -0.3 | -0.2 | -0.3                                |
|  | 1                     | 39.2                | +0.1  | +0.3 | +0.3 | +0.3                                |
| 10% sodium salicylate . . . . .                                    | 1.43                  | 39.3                | 0.0   | -0.6 | -0.9 | -0.9                                |
|  | 1.75                  | 39.5                | -0.2  | -0.5 | -0.9 | -0.9                                |
|  | 1.45                  | 39.6                | -1.6  | -1.8 | -1.8 | -1.8                                |
| Same diluted 1:10 . . . . .  | 1.32                  | 39.7                | 0.0   | -0.2 | -0.4 | -0.4                                |
|  | 1.25                  | 39.7                | -0.1  | -0.1 | -0.2 | -0.2                                |
|  | 1.62                  | 39.4                | +0.5  | +0.4 | +0.1 | +0.5                                |

## DISCUSSION

As it is well known convulsant drugs (picrotoxin, strychnine etc.) produce changes in heat regulation. Small doses increase heat loss, larger doses further increased loss of heat and paralytic doses diminish the heat production greatly. The temperature is changed accordingly: paralytic doses lower it greatly (Sollman 2). No such effect is described in the literature we had in our access for sedative drugs as it is our case. Recently it has been shown by J. ten Cate and J. Boeles 3) that pentothal and nembutal lower the body temperature of rats.

We know of course that the bromides show many of the actions which are typical of the depressant drugs of the hydrocarbon anaesthetics. The action of the bromide ion on the central nervous system is one of depression.

The experiments of Januschke cited by Bürgi (4) have demonstrated that sodium bromide and calcium bromide abolish the clonic spasms which cocaine causes to rabbits. The necessary amounts are smaller than the required to provoke sleep.

Our experiments show that the depressant action of the bromide ion which lowers the body temperature in rabbits can be abolished by diluting the solution to be tested 1:5 or 1:10 with pyrogen free distilled water. The same is true for sodium salicylate solutions. One could object that by diluting the solution, the concentration of pyrogen is also diluted. From theoretical point of view this objection is correct, but it has no practical value, because the minimal effective dose of pyrogen for humans is several hundred times greater than the dilution we make (5).

Further the antipyretic action of bromides on rats has been demonstrated. This antipyretic effect is enhanced by calcium ions. The calcium itself has no such effect as we have observed in very great number of pyrogen tests.

We suggest that if the same technique is applied to antipyretic drugs may prove itself useful for pyrogen tests. The problem is further complicated by the discovery of Wylie and Todd (6) that *Proteus vulgaris* and *Pseudomonas fluorescens* can produce a depressant substance, which either lowers the body temperature to below normal, or prevents the pyrogen from causing a rise in body temperature. The modifying effect of the depressant

was abolished by heating the solution between 30° and 40° C for about 10 minutes before the injection.

## REFERENCES

1. *L. J. De Merre et T. Probey*, Les pyrogènes, 1945, p. 36.
2. *T. Sollmann*, A manual of Pharmacology, 1948 p. 501.
3. *J. ten Cate and J. Boeles*, Arch. internat. de Pharmacodynamie et Therapie, **77**, 1948 p. 468 — 76.
4. *Bürgi*, Brom in Heffters Handbuch der experimentellen Pharmakologie, Band 3, 1 Hälfte 1927, p. 303.
5. Loc. cit. 1 p. 43.
6. *Wylie and Todd*. An examination of pyrogen from various sources. The Journal of Pharm. and Pharmacol. Vol. 1, Nov. 1949, p. 818.

## ΠΕΡΙΛΗΨΙΣ

Κατὰ τὴν δοκιμασίαν διὰ τὴν ἀνίχνευσιν πυρετογόνων ἐντὸς διαλυμάτων περιεχόντων μείγμα 3%  $\text{CaBr}_2$  καὶ 5% γλυκονικοῦ ἄσβεστιοῦ εὔρομεν ὅτι ἡ θερμοκρασία τῶν κονίκλων κατέρχεται κατὰ 1 — 3° C κάτω τῆς ἀρχικῆς τοιαύτης. Σκοπὸς τῆς παρούσης ἐρεύνης ὑπῆρξεν ἡ διαλεύκανσις τῶν ἑξῆς τριῶν σημείων: 1) ἐὰν ἡ ἐνέργεια αὕτη τῶν βρωμιούχων ἀναστέλλει τὴν ὑψωσιν τῆς θερμοκρασίας ἐκ πυρετογόνων οὐσιῶν. 2) διὰ ποίας μεθόδου δύναται νὰ ἀνασταλῆ ἡ ἐνέργεια αὕτη καὶ 3) ἐὰν τὰ βρωμιούχα ἔχουν ἀντιπυρετικὴν ἐνέργειαν.

**Ἀποτελέσματα:** Εὐρέθη πρῶτον ἡ μέση θανατηφόρος δόσις DL 50 ἐπὶ ἐπιμύων.

- 1) τοῦ μείγματος 3%  $\text{CaBr}_2$  καὶ 5% γλυκονικοῦ ἄσβεστιοῦ.
- 2) τοῦ σαλικυλικοῦ νατρίου.
- 3) τοῦ ἀκετυλοσαλικυλικοῦ ὀξέος.

Ἀπὸ πειράματα ἐπὶ ἐπιμύων εἰς τοὺς ὁποίους προεκλήθη πειραματικῶς πυρετὸς εὐρέθη ὅτι πράγματι τὰ ἀνόργανα ἅλατα τοῦ βρωμίου ἔχουν ἀντιπυρετικὴν ἐνέργειαν εἰς τὰς χρησιμοποιηθείσας δόσεις. Τὴν ἐνέργειαν ταύτην ἐπαυξάνει ἡ σύγχρονος χορήγησις ἐνώσεων ἄσβεστιοῦ.

Διὰ πειραμάτων ἐπὶ κονίκλων εὐρέθη ὅτι ἡ ἐνέργεια τῶν βρωμιούχων ἐπὶ τῆς θερμοκρασίας τοῦ σώματος ἀναστέλλει τὴν ἐνέργειαν τῶν πυρετογόνων οὐσιῶν ἐπὶ τῆς θερμοκρασίας, οὕτω δὲ συσκοτίζεται τὸ ἀποτέλεσμα τῆς δοκιμασίας

διὰ τὴν ἀνίχνευσιν πυρετογόνων. Δι' ἀραιώσεως τοῦ ὑπ' ἐξέτασιν διαλύματος 1 : 5 ἢ 1 : 10 δι' ὕδατος ἀπεσταγμένου καὶ ἐλευθέρου πυρετογόνων οὐσιῶν, δὲν παρατηρεῖται πλέον ἢ ἐνέργεια αὕτη τῶν βρωμιούχων ἢ σαλικυλικῶν ἐπὶ τῆς μοκρασίας, οὕτω δὲ τὸ ἀποτέλεσμα τῆς ἐξετάσεως διὰ πυρετογόνους οὐσίας δὲν διαταράσσεται. Ἡ παρατήρησις ὅτι δι' ἀραιώσεως τοῦ διαλύματος ἀραιοῦται καὶ ἡ πυκνότης εἰς πυρετογόνους οὐσίας δὲν ἔχει πρακτικὴν ἀξίαν, διότι ἡ ἐλαχίστη δόσις ἣτις προκαλεῖ πυρετογόνον ἀντίδρασιν ἐπὶ ἀνθρώπων εἶναι πολλαπλασία τῆς λαμβανομένης ἀραιώσεως.

*Γεωργ. Μαρίνου*, Συνθῆκαι γενέσεως τοῦ ὀρνυκτοῦ Οὐβιροβίτου ἐντὸς χρωμιατικοῦ κοιτάσματος παρὰ τὸν Δομοκόν\*.

\* Θὰ δημοσιευθῇ κατωτέρω.